PDCD1 and neoplasm: Additionally, we have shown that the combination of anti-PD-1 therapy with RIT using 213Bi-labeled h8C3, a humanized mAb targeting melanin, slows down tumor growth by 1.5 fold times and improves survival in this model [13].